Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-02-06
2007-02-06
Schultz, James (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S006120, C435S091100
Reexamination Certificate
active
10149352
ABSTRACT:
The invention provides antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene.
REFERENCES:
patent: 5874553 (1999-02-01), Peyman et al.
patent: 6007995 (1999-12-01), Baker et al.
patent: 6127346 (2000-10-01), Peyman et al.
patent: 6265157 (2001-07-01), Prockop et al.
patent: 2004/0005663 (2004-01-01), Bell et al.
patent: 736608 (1996-10-01), None
patent: WO 93/11149 (1993-06-01), None
patent: WO 94/11494 (1994-05-01), None
patent: WO 94/22487 (1994-10-01), None
patent: WO 98/33904 (1998-08-01), None
patent: WO 99/49065 (1999-09-01), None
Opalinska et al. Nucleic acid therapeutics: Basic principles and recent applications. Nature Review, 2002, vol. 1, pp. 503-514.
Crooke, S.T. Progress in antisense technology 2004 Annu. Rev. Med. vol. 55, pp. 61-95.
Jen et al. Supression of gene expression by targeted disruption of messenger RNA: Available options and current strategies 2000 Stem Cells vol. 18: pp. 307-319.
Agrawal et al. Antisense therapeutics: is it as simple as complementary base recognition? 2000 Mol. Med. Tod. vol. 6: pp. 72-81.
Altmann, K.H. et al., “Novel Chemistry”, pp. 73-107, 1998., XP-002119324.
Ausserlechner, MJ et al.., “Altered Procollagen mRNA Expression during the Progression of Avian Scleroderma”,Molecular Medicine, vol. 3, No. 10, pp. 654-662, 1997., XP-000986380.
Colige, A. et al., “Use of Antisense Oligonucleotide To Inhibit Expression of a Mutated Human Procollagen Gene (COL1A10 in Transfected Mouse 3T3 Cels”,Biochemistry, vol. 32, No. 1, pp. 7-11, 1993., XP-000652779.
Hawkins, JR. et. al., “A 9-Base Pair Deletion in COL1A1 in a Lethal Variant of Osteogenesis Imperfecta”,The Journal of Biological Chemistry, vol. 266, No. 33, pp. 22370-22374, 1991., XP-000942166.
Khillan, JS. et al., “Partial Rescue of a Lethal Phenotype of Fragile Bones in Transgenic Mice with a Chimeric Antisense Gene Directed Against a Mutated Collagen Gene”,Proc. Natl. Acad. Sci. USA., vol. 91, pp. 6298-6302, 1994., XP-000942172.
Laptev, AV. Et. al., Specific Inhibition of Expression of a Human Collagen Gene (COL1A1) with Modified Antisense Oligonucleotides. The Most Effective Target Sites Are Clustered in Double-Stranded Regions of the Predicted Secondary Structure for the mRNA,Biochemistry, vol. 33, pp. 1033-11039, XP-000984496, 1994., XP-000984496.
Onoda, K. et. al., “Role of Extracellular Matrix in Experimental Vasospasm: Inhibitory Effect of Antisense Oligonucleotide on Collagen Induction”,Stroke, vol. 37, No. 11, pp. 2102-2108, 1994., XP-000984053, 1996.
Prockop, DJ. et. al., “Mutations in Type 1 Procollagen That Cause Osteogenesis Imperfecta: Effects of the Mutations on the Assembly of Collagen into Fibrils, the Basis of Phenotypic Variations, and Potential Antisense Therapies”,Journal of Bone and Mineral Research, vol. 8, Sapp.. 2, pp. S489-S492, 1993., XP-000674592.
Ririe, SS. and Guntaka, RV., “An RNA Oligonucleotide Corresponding to the Polypyrimidine Region of the Rat α 1 (1) Procollagen Promoter Forms a Stable Triplex and Inhibits Transcription”,Biochemical and Biophysical Research Communications, vol. 249, pp. 218-221, 1998., XP-000942267.
Uhlmann, E. and Peyman, A., “Antisense Oligonucleotides: A New Therapeutic Principle”,Chemical Reviews, vol. 90, No. 4, pp. 543-584, 1990., XP-000141412.
Nath Rahul Kumar
Schultz James
The Matthews Firm
Vivlemore Tracy
LandOfFree
Antisense oligonucleotides to type I procollagen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides to type I procollagen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides to type I procollagen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816921